Tiziana Life Sciences' 6-K reveals progress on nasal anti-CD3 foralumab, targeting long COVID. Key insights on innovative treatment and market potential included.
Tiziana Life Sciences LTD announces a product development partnership with Renaissance Lakewood for optimizing foralumab, targeting neurodegenerative conditions via intranasal delivery.
Tiziana Life Sciences LTD's Form 6-K reveals progress in their ISPPEA program for treating non-active secondary progressive MS, with promising patient outcomes.
Tiziana Life Sciences' 6-K report reveals highlights from a news feature on foralumab, showcasing patient experiences in Alzheimer's treatment and enhancing public awareness of innovative therapies.
Tiziana Life Sciences LTD's 2025 foreign issuer report highlights findings on nasal anti-CD3 monoclonal antibody, addressing GLP-1 drug tolerability issues. Read more in Exhibit 99.1!
Tiziana Life Sciences LTD announces a review on intranasal foralumab for neurodegenerative diseases, published in Nature Reviews Neurology. Key insights and implications for investors.
Discover Tiziana Life Sciences' latest Form 6-K report detailing a major milestone in Alzheimer's research with intranasal foralumab. Key insights and implications for investors.